Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Glaucoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Glaucoma
    Silent Cerebral Infarcts a Risk Factor for Visual Field Loss in Patients With Normal-Tension Glaucoma - (DGNews)
    Dosing Aid Provides Accurate Snapshot of Travoprost Compliance in Patients With Primary Open-Angle Glaucoma: Presented at COS - (DGDispatch)
    Buccal Membrane Is Effective in Repair of Leaking Trabeculectomy Blebs, Exposed Glaucoma Drainage Devices: Presented at COS - (DGDispatch)
    TopAbstracts in Glaucoma 06/29/2009 - (DGNews)
    Antiglaucoma Medications Do Not Adversely or Favourably Affect Selective Laser Trabeculoplasty Success: Presented at COS - (DGDispatch)

    News archive

     Recent webcasts/CME - Glaucoma
      Managing Ocular Surface Disease in the Glaucoma Patient
      Adjunctive Medical Therapy: New Evidence and Treatment Strategies for Glaucoma
      Enhancing Adherence with Glaucoma Therapy: Practical Strategies for Superior Outcomes

      Webcasts/CME archive

       Recent cases - Glaucoma
        Topiramate-Associated Acute Glaucoma in a Migraine Patient Receiving Concomitant Citalopram Therapy: A Case-Report
        Central Retinal Artery Occlusion and Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with an Overlap Syndrome: A Case Report
        Argon Laser Peripheral Iridoplasty for Plateau Iris Associated with Iridociliary Cysts: A Case Report
        Missed Case of Axenfeld-Rieger Syndrome: A Case Report
        Good Functional Recovery Following Intervention for Delayed Suprachoroidal Haemorrhage Post Bleb Needling: A Case Report

        Cases archive
          




        my personal edition > glaucoma > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Ibopamine More Potent Mydriatic Than Phenylephrine Or Tropicamide

        A DGReview of :"Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment."
        Investigative Ophthalmology and Visual Science (IOVS)

        01/13/2003
        By Mark Greener


        Ibopamine alone has a more potent mydriatic effect and increase in intraocular pressure in patients with glaucoma than do either phenylephrine or tropicamide.

        Researchers from the University of Verona, Italy, enrolled 15 patients with primary open-angle glaucoma and 15 healthy subjects, aged between 40 and 70 years (mean 54.8), into this open prospective study. Assessments were mad of visual acuity, refraction, intraocular pressure (IOP), pupil diameter and anterior segment geometry after instillation of 2% ibopamine. Between 20 and 30 days later, five controls and five glaucoma patients underwent the same assessments using first 10% phenylephrine followed by 1% tropicamide.

        Another group of 15 healthy controls, aged between 45 and 70 years (mean 53.5) was recruited. In this group, the researchers measured pupil diameter following various doses of ibopamine, phenylephrine and tropicamide.

        Forty minutes after treatment with 2% ibopamine, average pupil size increased from 5.0 to 9.1 mm. This mydriasis was greater than either 10% phenylephrine (4.7 to 7.9 mm) or 1% tropicamide (4.6 to 6.9 mm). Ibopamine did not alter either refraction or visual acuity.

        In glaucoma patients, IOP rose from 22.2 to 24.8 mm Hg following ibopamine. After instillation of 1% tropicamide, IOP increased from 21.2 to 23.6 mm. However, 10% phenylephrine did not produce any statistically significant change in IOP.

        Ibopamine 2% increased iris thickness, while reducing the depth of the sulcus ciliaris and posterior chamber. The anterior chamber angle widened by a mean of 5 degrees. The scleral-iris and sclera-ciliary process angles both increased. The pupil border and lens surface separated in 37% of cases. In the remainder, contact with the zonule only remained.

        Phenylephrine 10% produced a similar pattern of changes. However, only the increase in iris thickness and scleral-iris angle reached statistical significance. Tropicamide slightly increased the scleral-iris angle, which was also statistically significant.

        The authors concluded that 2% ibopamine is a more potent mydriatic than either 10% phenylephrine or 1% tropicamide. Ibopamine also increases IOP in glaucoma patients. The findings suggest that ibopamine widens the anterior chamber angle by posterior rotation of the iris plane and ciliary processes. Ibopamine's more marked effect compared to phenylephrine and tropicamide seems to underlie the greater mydriasis.
        Invest Ophthalmol Vis Sci 2003;44:281-9. "Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send